NASDAQ:ACER Acer Therapeutics (ACER) Stock Price, News & Analysis → AI to Meet the Same Fate as EVs? (From Porter & Company) (Ad) Free ACER Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.66▼$0.8550-Day Range$0.66▼$0.9052-Week Range$0.55▼$4.56Volume574,600 shsAverage VolumeN/AMarket Capitalization$16.15 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 Stock AnalysisStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial Media Get Acer Therapeutics alerts: Email Address Ad Porter & CompanyAI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… Simply click here to read Porter’s warning on The Big AI Die-Up now. About Acer Therapeutics Stock (NASDAQ:ACER)Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. The company's pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-801 for the treatment of induced Vasomotor Symptoms, post-traumatic stress disorder, and prostate cancer; and OLPRUVA, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease. It has a license agreement with Sanofi to acquire worldwide rights to Osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist; an option agreement with Relief for the development, regulatory approval, and commercialization of OLPRUVA; and an agreement with Emory University to acquire the worldwide intellectual property rights to a family of patents and patent applications related to the use of neurokinin receptor antagonists in managing conditioned fear and treating anxiety disorders, including post-traumatic stress disorder. The company was incorporated in 1991 and is headquartered in Newton, Massachusetts.Read More Ad Porter & CompanyAI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… Simply click here to read Porter’s warning on The Big AI Die-Up now. ACER Stock News HeadlinesFebruary 22, 2024 | msn.comHow to score 50% off The Legend of Zelda: Breath of the WildJanuary 6, 2024 | benzinga.comAcer Therapeutics Inc Stock (OTC:ACER), Guidance and ForecastMarch 28, 2024 | Porter & Company (Ad)AI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… January 6, 2024 | benzinga.comAcer Therapeutics Inc Stock (OTC:ACER) Dividends: History, Yield and DatesJanuary 4, 2024 | finance.yahoo.comZevra Therapeutics Appoints Global Medical Leader, Adrian Quartel, M.D., FFPM, as Chief Medical OfficerDecember 31, 2023 | morningstar.comRelief Therapeutics Holding SA RLFNovember 18, 2023 | benzinga.comAcer Therapeutics Stock (NASDAQ:ACER) Insider TradesNovember 7, 2023 | markets.businessinsider.comZevra Therapeutics Reports Corporate Updates and Third Quarter 2023 Financial ResultsMarch 28, 2024 | Porter & Company (Ad)AI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… November 7, 2023 | finance.yahoo.comZevra Therapeutics Inc (ZVRA) Reports Q3 2023 Financial ResultsNovember 2, 2023 | finance.yahoo.comLeading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Acer Therapeutics Shareholders Vote "FOR" the Proposed Merger and Related ProposalsNovember 1, 2023 | sg.finance.yahoo.comAcer Therapeutics Inc. (ACER)September 6, 2023 | 247wallst.comHC Wainwright Downgrades Acer TherapeuticsSeptember 5, 2023 | 247wallst.comRoth MKM Downgrades Acer TherapeuticsSeptember 5, 2023 | msn.comZevra's Rare Find: Unearthing Value In Niche Rare Diseases The Market OverlooksSeptember 2, 2023 | msn.comRoth Capital Downgrades Acer Therapeutics (ACER)September 2, 2023 | msn.comRoth MKM Downgrades Acer Therapeutics (ACER)September 1, 2023 | msn.comAcer (ACER) to Get Acquired by Zevra for $91M, Stock UpSeptember 1, 2023 | msn.comAcer Therapeutics will reacquire OLPRUVA rights from Relief TherapeuticsAugust 31, 2023 | marketwatch.comZevra Therapeutics to Buy Acer Therapeutics >ZVRA ACERAugust 31, 2023 | markets.businessinsider.comUS Stocks Rise; Initial Jobless Claims Edge LowerAugust 31, 2023 | msn.comWhy Is Acer Therapeutics Stock Trading Higher Today?August 31, 2023 | technews.tmcnet.comACER Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Acer Therapeutics Inc. Is Fair to ShareholdersAugust 31, 2023 | marketwatch.comAcer Therapeutics Shares Take Flight on Zevra DealAugust 31, 2023 | seekingalpha.comAcer Therapeutics surges as Zevra agrees to acquire for up to $91MAugust 31, 2023 | msn.comZerva acquires Acer Therapeutics to bolster rare disease portfolioAugust 31, 2023 | msn.comAcer Therapeutics (NASDAQ:ACER) Skyrockets on Acquisition by Zevra TherapeuticsSee More Headlines Receive ACER Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acer Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/19/2021Today3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ACER CUSIPN/A CIK1069308 Webwww.acertx.com Phone(844) 902-6100Fax281-872-8585Employees30Year Founded2013Price Target and Rating Average Stock Price Target$1.50 High Stock Price Target$1.50 Low Stock Price Target$1.50 Potential Upside/Downside+657.5%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-26,240,000.00 Net MarginsN/A Pretax Margin-13,034.14% Return on Equity-29.93% Return on Assets-9.95% Debt Debt-to-Equity RatioN/A Current Ratio0.10 Quick Ratio0.02 Sales & Book Value Annual Sales$1.26 million Price / Sales12.81 Cash FlowN/A Price / Cash FlowN/A Book Value($1.05) per share Price / Book-0.63Miscellaneous Outstanding Shares24,460,000Free Float19,963,000Market Cap$16.15 million OptionableNot Optionable Beta0.21 Social Links The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Christopher Schelling (Age 47)Founder, President, CEO & Director Comp: $739.82kMr. Harry S. Palmin (Age 53)Chief Financial Officer Comp: $545.36kDr. Adrian Quartel FFPM (Age 56)M.D., Chief Medical Officer Comp: $421.65kMs. Tanya Hayden (Age 43)Chief Operating Officer Mr. John Michael Klopp (Age 48)Chief Technical Officer Mr. Donald R. Joseph J.D. (Age 69)Chief Legal Officer & Secretary Comp: $490.28kMr. Bernie Paul (Age 64)Chief People Officer Mr. Jefferson E. Davis (Age 56)Chief Business Officer Comp: $326.67kMr. Jason Kneeland CPAVP of Finance & ControllerMore ExecutivesKey CompetitorsNuCanaNASDAQ:NCNAPurple BiotechNASDAQ:PPBTFlora GrowthNASDAQ:FLGCTFF PharmaceuticalsNASDAQ:TFFPMIRA PharmaceuticalsNASDAQ:MIRAView All CompetitorsInstitutional OwnershipSimplex Trading LLCSold 2,000 shares on 2/2/2024Ownership: 0.000%View All Institutional Transactions ACER Stock Analysis - Frequently Asked Questions Should I buy or sell Acer Therapeutics stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acer Therapeutics in the last twelve months. There are currently 3 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ACER shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ACER, but not buy additional shares or sell existing shares. View ACER analyst ratings or view top-rated stocks. What is Acer Therapeutics' stock price target for 2024? 3 Wall Street research analysts have issued twelve-month target prices for Acer Therapeutics' stock. Their ACER share price targets range from $1.50 to $1.50. On average, they predict the company's share price to reach $1.50 in the next twelve months. This suggests a possible upside of 127.2% from the stock's current price. View analysts price targets for ACER or view top-rated stocks among Wall Street analysts. How were Acer Therapeutics' earnings last quarter? Acer Therapeutics Inc. (NASDAQ:ACER) released its quarterly earnings results on Friday, November, 19th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.28) by $0.05. What is Jason Chen's approval rating as Acer Therapeutics' CEO? 64 employees have rated Acer Therapeutics Chief Executive Officer Jason Chen on Glassdoor.com. Jason Chen has an approval rating of 99% among the company's employees. This puts Jason Chen in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Acer Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Acer Therapeutics investors own include Novavax (NVAX), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Sarepta Therapeutics (SRPT), Advanced Micro Devices (AMD), Amarin (AMRN), VBI Vaccines (VBIV), NVIDIA (NVDA), Idera Pharmaceuticals (IDRA) and Inovio Pharmaceuticals (INO). Who are Acer Therapeutics' major shareholders? Acer Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Chris Schelling and Steve Aselage. View institutional ownership trends. Does Acer Therapeutics have any subsidiaries? The following companies are subsidiares of Acer Therapeutics: Opexa Therapeutics Inc..Read More This page (NASDAQ:ACER) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryMost important medical advance in 100 yearsThe Oxford ClubFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acer Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.